Searched for
ANTIVIRAL DRUG UMIFENOVIR
Volatile phases come and go, structural tailwinds are a stronger play: 5 Indian pharma stocks with upside potential of up to 35%There are some sectors which have witnessed something which can be called “second inning”. Which is that in the last two decades, they did ...- After a long winter finally some tailwinds; 6 pharma stocks with upside potential of up to 31%While all pharma companies get classified into one sector they are very different at molecular level. Each company has its own operating ma...
- Drug firms get DGCI nod for Covid drug favipiravir despite inconclusive studyOn Tuesday, Hyderabad-based Biophore India Pharmaceuticals said it has received approval from the Drug Controller General of India (DGCI) t...
- Glenmark Pharma cuts price of COVID-19 drug by 27% to Rs 75 per tabletIn a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is Rs 75 per tab...
- Glenmark launches COVID-19 drug after DCGI nod; MRP at Rs 103 per tabletThe company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer p...
- COVID-19: CSIR institute to conduct clinical trials of antiviral drug UmifenovirThe drug has a good safety profile and acts by preventing entry of viruses into human cells and also by priming the immune system, accordin...
- Glenmark Pharma to study potential Covid-19 drug combinationThe study will look to enroll 158 hospitalized patients of moderate Covid-19 in India, the company added. Last month, Glenmark said it woul...
Load More